Opportunities — Why invest in R&D?
Investing in R&D means participating in asset creation before it reaches the market.
Research and development can transform scientific knowledge into intellectual property, new products, licensing opportunities, royalties, operational efficiency and competitive advantage.
Why R&D
Value begins before the final product.
01
Intellectual property
Creation of patents, technologies, formulations, processes, data and other intangible assets.
02
Competitive differentiation
Development of proprietary solutions and reduced dependence on third-party technologies.
03
New markets
The possibility of creating products, applications, licences and business models.
04
Value through maturity
Progress in evidence, prototype, validation and IP protection can reduce uncertainty and increase asset maturity.
05
Strategic partnerships
Connection between companies, universities, research institutions, researchers and specialised capital.
06
Innovation incentives
Possible use of incentive mechanisms, including Lei do Bem and other structures, when the project and organisations are eligible.
Ways to participate
Different paths to fund innovation.
01
Direct project funding
02
Co-development
03
Sponsored research
04
Partnership with a university or research institution
05
Licensing
06
Equity participation
07
Royalty-based structures
08
Corporate venture
09
Applicable tax incentives
10
Tokenised participation, when available and duly structured
None of these structures is presented as a guarantee of return. Availability depends on the project, the applicable regulation and the eligibility of the parties involved.
Risk & governance
R&D carries risk. The difference lies in how it is structured.
Scientific projects can face technical, regulatory, commercial, financial and execution risks. AXIOM organises those risks into stages, progression criteria, documentation, governance and monitoring of how resources are used.
| Risk | How it is identified | How it is monitored | Evidence required to advance |
|---|---|---|---|
| Scientific risk | Review of hypotheses, methodology and existing evidence. | Technical reviews per stage and independent scientific opinion. | Reproducible results for the defined endpoints. |
| Technological risk | TRL assessment, technical dependencies and scalability limits. | Engineering milestones and prototype iterations. | Functional prototype or process validated at the target scale. |
| Regulatory risk | Classification of the product and mapping of applicable requirements. | Regulatory dossier tracking and specialist review. | Required studies concluded and documentation accepted for filing. |
| Intellectual property risk | Prior art search, ownership review and freedom-to-operate analysis. | Filing calendar, office actions and ownership agreements. | Filed or granted rights with defined ownership. |
| Execution risk | Assessment of team, infrastructure, budget and timeline. | Development reports and tracking of the use of resources. | Milestones delivered within the agreed scope and budget. |
| Market risk | Analysis of the problem addressed, demand and differentiation. | Dialogue with potential users, partners and licensees. | Documented interest from users, partners or licensees. |
How AXIOM structures
One structure, nine stages.
AXIOM does not present science merely as an idea. Each asset is organised with documentation, maturity stage, risks, budget, milestones, indicators and possible paths for value generation.
Origination
Screening
Due diligence
Roadmap
Valuation
Governance
Capitalisation
Validation
Licensing or scale
Who is it for
Capital with a scientific mandate.
Companies with an innovation strategy
Industries under the Lucro Real regime
Family offices
Venture capital funds
Corporate venture
Impact investors
Philanthropic organisations
Universities and research institutions
Industrial and commercial partners
Transparency
Decisions supported by documentation.
Controlled Data Room
Scientific documentation
Intellectual property status
Budget and allocation of resources
Schedule and milestones
Development reports
Risk indicators
Governance and responsible parties
Relevant project updates
Connect capital, science and execution.
Discover scientific projects structured for validation, development, licensing and impact.